Kolltan Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Kolltan Pharmaceuticals's estimated annual revenue is currently $1.6M per year.(i)
  • Kolltan Pharmaceuticals's estimated revenue per employee is $155,000

Employee Data

  • Kolltan Pharmaceuticals has 10 Employees.(i)
  • Kolltan Pharmaceuticals grew their employee count by -9% last year.

Kolltan Pharmaceuticals's People

NameTitleEmail/Phone
1
Senior ScientistReveal Email/Phone
2
Principal ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-80%N/AN/A
#2
$4.3M288%N/AN/A
#3
$9.8M66-11%N/AN/A
#4
$1.4M9350%N/AN/A
#5
$16.6M107-23%N/AN/A
#6
$4.5M29-22%N/AN/A
#7
$1.7M1157%N/AN/A
#8
$2.3M15-6%N/AN/A
#9
$0.3M4-43%N/AN/A
#10
$4M260%N/AN/A
Add Company

What Is Kolltan Pharmaceuticals?

Kolltan, a privately held clinical-stage company, is focused on advancing a new generation of therapeutics in oncology and other diseases by discovering and developing novel biologic agents designed to modulate the function of receptor tyrosine kinases (RTKs). Kolltan is led by an experienced team of executives and scientists with a deep understanding of RTKs, their ligands, and cellular signaling. Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is working in close collaboration with the laboratory of Kolltan co-founder, Dr. Joseph Schlessinger, as well as the Yale medical and scientific community to bring important medicines to cancer patients and other patients with serious diseases. The Company's R&D pipeline is advancing rapidly, with the first clinical trial initiated in January 2014.

keywords:N/A

N/A

Total Funding

10

Number of Employees

$1.6M

Revenue (est)

-9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.5M10-17%N/A
#2
$0.9M100%N/A
#3
$1M100%N/A
#4
$1.3M110%N/A
#5
$1M1110%N/A